

CLAIMS

1. A composition containing a GLP-1 compound which composition is a gel.
- 5 2. A composition, according to Claim 1, which composition has thixotropic properties.
3. Composition, according to Claim 1 or 2, containing not less than about 2 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of a GLP-1 compound and, preferably, containing not more than about 100 mg/ml of a GLP-1 compound.
- 10 4. Composition, according to any one of the preceding claims, containing a phenolic or an alcoholic aromatic compound.
- 15 5. Composition, according to the preceding claim, wherein the phenolic or alcoholic aromatic compound is a pharmaceutically acceptable antimicrobial preservative.
6. Composition, according to the preceding claim, wherein the pharmaceutically acceptable antimicrobial preservative is benzyl alcohol, a cresol, e.g., m-cresol, a phenol, e.g., phenol or resorcinol, or a paraben, e.g., methyl paraben or propyl paraben.
- 20 7. Composition, according to any one of the preceding claims, wherein the thixotropic property only or mainly results from the presence of a GLP-1 compound.
- 25 8. Composition, according to anyone of the preceding claims, wherein the thixotropic property only or mainly results from the presence of a GLP-1 compound together with a pharmaceutically acceptable antimicrobial preservative.
9. Composition, according to anyone of the preceding claims, containing divalent metal ions, e.g. zinc, calcium, magnesium or cobalto ions.
- 30 10. Composition, according to the preceding claim, wherein the metal ions are zinc ions.
11. Composition, according to anyone of the preceding claims, containing 1 zinc ion per molecule of the GLP-1 compound or less and, preferably, they contain less than 0.4 zinc ion per molecule of the GLP-1 compound, more preferred they contain between 0.4 and 0.1 zinc

ion per molecule of the GLP-1 compound and most preferred between 0.2 and above 0.1 zinc ion per molecule of the GLP-1 compound.

12. A method for the treatment of diabetes mellitus in a mammal in need of such
5 treatment comprising the administration of a composition according to any one of the preceding claims containing an effective amount of the GLP-1 compound.

13. A method, according to the preceding claim, wherein the administration is performed by subcutaneous injection.

10

14. Any novel feature or combination of features described herein.

1995-12-20, ToN/KGF, IL

Novo Nordisk A/S
4343-WO,ToN

15